Karin Eastham Sells 3,729 Shares of Veracyte (NASDAQ:VCYT) Stock

Posted by Brian Himes on Jun 22nd, 2026

Veracyte, Inc. (NASDAQ:VCYT – Get Free Report) Director Karin Eastham sold 3,729 shares of the stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $52.89, for a total value of $197,226.81. Following the transaction, the director owned 15,097 shares in the company, valued at $798,480.33. This trade represents a 19.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Veracyte Price Performance

NASDAQ:VCYT traded down $0.37 during mid-day trading on Monday, reaching $53.26. The company’s stock had a trading volume of 954,513 shares, compared to its average volume of 1,005,825. The stock has a market cap of $4.25 billion, a P/E ratio of 48.86 and a beta of 1.98. The company’s fifty day simple moving average is $41.37 and its two-hundred day simple moving average is $39.42. Veracyte, Inc. has a twelve month low of $22.61 and a twelve month high of $54.72.

Veracyte (NASDAQ:VCYT – Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.34 by $0.18. The company had revenue of $139.07 million during the quarter, compared to the consensus estimate of $130.36 million. Veracyte had a net margin of 16.25% and a return on equity of 9.07%. The company’s quarterly revenue was up 21.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.31 EPS. Sell-side analysts expect that Veracyte, Inc. will post 1.29 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have weighed in on VCYT. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Veracyte in a research note on Friday, March 27th. Wolfe Research initiated coverage on Veracyte in a report on Tuesday, June 2nd. They set an “outperform” rating and a $55.00 price objective for the company. Guggenheim cut their target price on Veracyte from $50.00 to $45.00 and set a “buy” rating on the stock in a research report on Monday, March 30th. Needham & Company LLC lifted their target price on Veracyte from $48.00 to $57.00 and gave the company a “buy” rating in a report on Monday, June 1st. Finally, UBS Group boosted their price target on Veracyte from $48.00 to $52.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $47.57.

Check Out Our Latest Research Report on VCYT

Institutional Trading of Veracyte

A number of institutional investors have recently added to or reduced their stakes in the business. First Trust Advisors LP raised its holdings in shares of Veracyte by 23.6% during the 3rd quarter. First Trust Advisors LP now owns 1,324,965 shares of the biotechnology company’s stock valued at $45,486,000 after buying an additional 253,033 shares during the period. Artisan Partners Limited Partnership boosted its holdings in Veracyte by 16.6% in the 3rd quarter. Artisan Partners Limited Partnership now owns 7,370,467 shares of the biotechnology company’s stock worth $253,028,000 after acquiring an additional 1,048,692 shares during the period. Westview Management dba Westview Investment Advisors acquired a new stake in Veracyte in the fourth quarter valued at approximately $1,376,000. Iron Triangle Partners LP acquired a new stake in Veracyte in the third quarter valued at approximately $16,650,000. Finally, JPMorgan Chase & Co. raised its stake in shares of Veracyte by 54.0% during the third quarter. JPMorgan Chase & Co. now owns 518,850 shares of the biotechnology company’s stock valued at $17,812,000 after purchasing an additional 181,872 shares during the period.

About Veracyte

(Get Free Report)

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.